(a virtual meeting)
- Patient selection to guide more efficient clinical trial design
- Increase therapeutic window – enriching for responders and limiting safety signals
- Guiding selection of IO combination strategies
Vice President, Cell Biology & Immunology
Paul has 25 years-experience in biotech, coordinating discovery and development of biologics. He began his career at HGS, directing genomic-based target discovery of various protein and mAb-based therapeutics including discovery of BLyS as a B-cell survival factor leading to development of Benlysta, an approved treatment for lupus. At MacroGenics, Paul leads research dedicated to the discovery, preclinical development and clinical translational biology of antibody-based therapeutics for cancer or autoimmune disease through harnessing of the host immune system. He obtained a PhD from University of Glasgow and performed post-doctoral work at the Roche Institute of Molecular Biology. Paul has co-authored over 70 peer-reviewed manuscripts and has 40 issued US patents.
- Importance of stratification by immune response for therapeutics and treatment?
- How do cancer cells avoid the immune attack?
- Can early detection of low level immune biomarkers be an early indicator of cancer?
- How do you best screen and study the immune response?
Stefan Jellbauer, Product Manager
Thermo Fisher Scientific
Stefan Jellbauer is the Product Manager for QuantiGene gene expression assays. After 10 years in academic research, he joined Affymetrix/eBioscience in 2015, where he worked in the roles of Field Application Scientist and Technical Specialist with Affymetrix and Thermo Fisher Scientific before transitioning to Business Development in personalized cancer research and therapeutics with Farcast Biosciences as Technical Scientific Liaison. He now works in Global Product Management.
Stefan received his Ph.D. in Biology from Ludwig-Maximilians University in Munich (Germany), focusing on tumor vaccination. He completed his post-doctoral work at the University of California, Irvine studying mucosal immunology and host-pathogen interactions.
1:00pm – 1:30pm
Recent breakthroughs in checkpoint inhibition, CAR T cell therapy, and cancer vaccines illuminate the full capabilities of the immune system and how it may be harnessed to combat cancer. Identifying and validating predictive biomarkers for checkpoint immunotherapy is important to optimize therapeutic benefit, minimize toxicity risk, and guide combination therapy approaches.
Thermo Fisher Scientific offers many research platforms and products to help better understand the interplay between the immune system and cancer.
ELISAs, Invitrogen high-sensitivity ProQuantum and multiplex ProcartaPlex immunoassays are routinely used for quantitative assessment of soluble proteins such as cytokines, chemokines, growth factors, and other biomarkers.
In addition to protein profiling, molecular profiling of tumors and their microenvironment can lead to the identification of gene signatures and/or markers that can help predict response or elucidating the mechanisms of resistance to therapy. Invitrogen bead-based Quantigene Plex assay use Luminex xMAP and branched DNA technology for-high-throughput gene expression profiling. to analyze gene signatures, RNA biomarkers in multiple pathways, and cell type-specific markers.
This presentation will focus on “finding the appropriate answer (immunoassay) to a particular question (biomarker discovery in areas of Immuno-Oncology)”.
- Cancer is heterogeneous and adaptable and its interaction with a dynamic human immune system is not predictably modeled in animals or in isolated cells. What technologies or models are available or emerging for non-clinical experiments that add value for hypothesis generation and PK/PD modeling?
- The dynamic nature of the immune system poses challenges in clinical trial design. What concepts, experimental approaches or protocol elements have you found useful in the design of your trials for answering key translational questions, such as what is the optimal dose and schedule for my novel agent?
- What do you see as the key operational, technical and biologic challenges to success of current and emerging immuno-oncology drugs?
Vice President, Translational Biology
Mary Simcox, Ph.D. has over 20 years of experience in oncology drug discovery and development. At Hoffmann La Roche, she led small molecule drug and antibody discovery and preclinical development teams and the Global Oncology Target Selection Team. Mary was the Roche Head of Cancer Cell Signaling and the lead scientist on several development teams, including the Roche biomarker lead for Avastin. After the Roche NJ site closure, Mary moved to Boston, where she has held roles at 3 biotechnology companies. For the past 3 years, Mary has been the VP of Translational Medicine at Cue Biopharma, where she has led the CUE-101 program from research to IND filing to phase I development.
4:50pm – 5:20pm
Closing Keynote & Address: TBC